Evolus, Inc. (EOLS)
USD 12.08
(2.37%)
USD 12.08
(2.37%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 120.35 Million USD | 67.45% |
| 2022 | 71.87 Million USD | -2.18% |
| 2021 | 73.47 Million USD | 68.32% |
| 2020 | 43.65 Million USD | -54.22% |
| 2019 | 95.34 Million USD | 464.04% |
| 2018 | 16.9 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 120.63 Million USD | 0.23% |
| 2024 Q2 | 120.91 Million USD | 0.23% |
| 2023 Q3 | 95.09 Million USD | -0.4% |
| 2023 Q2 | 95.47 Million USD | 30.81% |
| 2023 Q4 | 120.35 Million USD | 26.57% |
| 2023 Q1 | 72.98 Million USD | 1.54% |
| 2023 FY | 120.35 Million USD | 67.45% |
| 2022 Q2 | 73.29 Million USD | -0.13% |
| 2022 Q4 | 71.87 Million USD | -1.81% |
| 2022 Q1 | 73.39 Million USD | -0.12% |
| 2022 FY | 71.87 Million USD | -2.18% |
| 2022 Q3 | 73.2 Million USD | -0.13% |
| 2021 Q1 | 2.93 Million USD | -93.27% |
| 2021 FY | 73.47 Million USD | 68.32% |
| 2021 Q4 | 73.47 Million USD | 2853.3% |
| 2021 Q3 | 2.48 Million USD | -8.33% |
| 2021 Q2 | 2.71 Million USD | -7.56% |
| 2020 FY | 43.65 Million USD | -54.22% |
| 2020 Q3 | 136.29 Million USD | 41.7% |
| 2020 Q4 | 43.65 Million USD | -67.97% |
| 2020 Q1 | 95.77 Million USD | 0.45% |
| 2020 Q2 | 96.18 Million USD | 0.43% |
| 2019 Q4 | 95.34 Million USD | 0.45% |
| 2019 Q2 | 94.41 Million USD | 5.21% |
| 2019 FY | 95.34 Million USD | 464.04% |
| 2019 Q1 | 89.73 Million USD | 430.87% |
| 2019 Q3 | 94.92 Million USD | 0.53% |
| 2018 Q3 | 16.79 Million USD | 1.95% |
| 2018 Q1 | 16.14 Million USD | 0.0% |
| 2018 FY | 16.9 Million USD | 0.0% |
| 2018 Q4 | 16.9 Million USD | 0.67% |
| 2018 Q2 | 16.47 Million USD | 1.99% |
| 2017 FY | - USD | 0.0% |
| 2017 Q3 | 11.71 Million USD | -90.43% |
| 2017 Q2 | 122.43 Million USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | -100.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 501.54 Million USD | 76.002% |
| Theratechnologies Inc. | 51.26 Million USD | -134.796% |
| Safety Shot Inc | 304.9 Thousand USD | -39374.004% |
| Cosmos Health Inc. | 3.03 Million USD | -3865.255% |
| Cronos Group Inc. | 1.55 Million USD | -7620.269% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 75.847% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -252.03% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -98.138% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -1073.318% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -138243.678% |
| Dynavax Technologies Corporation | 252.41 Million USD | 52.318% |
| Radius Health, Inc. | 339.66 Million USD | 64.565% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -102657.643% |
| Alvotech | 1.02 Billion USD | 88.289% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -22228.606% |
| Alpha Teknova, Inc. | 13.25 Million USD | -808.301% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -803.189% |
| SCYNEXIS, Inc. | 12.15 Million USD | -889.876% |
| Harrow Health, Inc. | 183.17 Million USD | 34.292% |
| Biofrontera Inc. | 804 Thousand USD | -14870.025% |
| DURECT Corporation | 2.7 Million USD | -4354.441% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -262.571% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 61.133% |
| OptiNose, Inc. | 611 Thousand USD | -19598.691% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -26352.527% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -32.152% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -841.471% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -35722.09% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 0.125% |
| Shineco, Inc. | 10.01 Million USD | -1101.508% |
| Phibro Animal Health Corporation | 458.28 Million USD | 73.737% |
| Procaps Group S.A. | 28.41 Million USD | -323.65% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -1742.606% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Viatris Inc. | 16.18 Billion USD | 99.256% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -22228.606% |
| Rockwell Medical, Inc. | 8.29 Million USD | -1351.333% |
| Incannex Healthcare Limited | 210 Thousand USD | -57213.81% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -1006.546% |
| Tilray Brands, Inc. | 287.93 Million USD | 58.199% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 75.435% |
| PetIQ, Inc. | 437.82 Million USD | 72.509% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 53.403% |
| Journey Medical Corporation | 14.62 Million USD | -723.136% |
| Alimera Sciences, Inc. | 64.48 Million USD | -86.635% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -1655.179% |
| Assertio Holdings, Inc. | 38.51 Million USD | -212.507% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -88996.077% |
| Embecta Corp. | 1.62 Billion USD | 92.595% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -535209.553% |
| Procaps Group, S.A. | 28.41 Million USD | -323.65% |
| PainReform Ltd. | 30 Thousand USD | -401096.667% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -267.396% |
| Hempacco Co., Inc. | 5.93 Million USD | -1929.32% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 76.575% |
| Alvotech | 1.02 Billion USD | 88.289% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 80.465% |
| Kamada Ltd. | 7.43 Million USD | -1518.163% |
| Indivior PLC | 235.66 Million USD | 48.928% |
| Currenc Group, Inc. | 2.5 Million USD | -4700.967% |
| Evoke Pharma, Inc. | 5 Million USD | -2307.18% |
| Flora Growth Corp. | 942 Thousand USD | -12676.964% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -535209.553% |
| HUTCHMED (China) Limited | 48.18 Million USD | -149.764% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 79.572% |
| Akanda Corp. | 2.49 Million USD | -4719.845% |